close

Fundraisings and IPOs

Date: 2011-11-08

Type of information: Subvention

Company: ORCA Therapeutics (The Netherlands)

Investors: Agentschap NL (The Netherlands)

Amount: € 5 million

Funding type: credit

Planned used:

This credit will allow ORCA Therapeutics to take the next steps in preclinical and clinical development of its ORCA-010 product for treatment of prostate cancer patients.

Others:

ORCA Therapeutics, a pioneer in the development of innovative virotherapies for treatment of cancer, has received an innovation credit of up to € 5 million from Agentschap NL, an agency executing programmes for the Dutch Ministry of Economic Affairs, Agriculture and Innovation, to support development of its lead compound ORCA-010 for prostate cancer. The innovation credit is a credit facility from Agentschap NL dedicated to highly innovative projects. Under the terms of the agreement, ORCA receives € 1,058,000 to support the initial stage of the project, with the outlook for additional funding up to € 5 Million upon successful completion of specific milestones. The credit will become repayable subject to the commercial success of the project.

Therapeutic area: Cancer - Oncology

Is general: Yes